1.16 USD
▲+0.41+53.56%
盘后 1.03 0.00%
2026-09-16
市值
$19.34M
市盈率
—
EPS
-4.56
股息率
—
52 周区间
0.74 – 12.23
成交量
93.93M
Beta
-1.66
目标价
—
52W 低 0.7452W 高 12.23
价格走势
公司简介
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr...